Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients.
Subscribe to our email newsletter
As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally.
This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients.
It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain.
With 10 manufacturing facilities in India, US and Canada and a team of about 6,000 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries.